Compared with the combination treatments of anti‐PD‐1 plus anti‐RANKL antibodies dosed at 100 μg of each antibody (i.e. 200 μg of total antibody), treatment with the anti‐RANKL/PD‐1 BsAb with an equivalent overall antibody dose (200 μg) achieved at least an equivalent improvement in control of RM1 prostate cancer (Figure 2a) or B16F10 melanoma (Figure 2b) lung metastases. The gene discussed is PDCD1; the disease is melanoma.